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agents in which pre- and perinatal treatment of mice
with anti-Ig polyclonal reagents successfully depleted
surface positive B lineage cells (Cooper et al., 1980).
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Genentech, Inc. Such a strategy was not applicable to adult animals that
have high levels of circulating Igs that function as a sinkOne DNA Way, MS-34
South San Francisco, California 94080 for the depleting anti-Ig reagents. Attempts to translate
these observations into clinical use for B cell lymphomas
focused initially around the idea of anti-idiotype (Id) anti-
bodies passively delivered or induced through activeThe pathogenic roles of B cells in human autoimmune
diseases involve a multitude of mechanistic pathways immunization (anti-Id vaccines) (McCarthy et al., 2003).
Although this approach seemed ideal from a scientificand include the well-established contributions of auto-
antibodies and immune complexes that induce local perspective, the preexisting suppressed immune sys-
tems of cancer patients, phenomenon of tumor escape,inflammatory reactions and tissue destruction. Recent
results using several novel B cell-directed therapies as well as manufacturing related factors have delayed
the translation of these therapies to clinical practice.have provided new insights into additional roles of B
cells in human autoimmunity. In this review, we will The alternative approach of using antibodies directed
against pan-B cell targets was faster to reach fruitionhighlight some of these studies and discuss how clini-
cal insights parallel murine models of normal immunity through the development of antibodies targeting the
CD20, CD22, and CD52 surface molecules (Treon andand autoimmunity.
Anderson, 2000; Juweid, 2003; Cersosimo, 2003; Robak,
2004). All these approaches rely on the ability of pas-Treatment of autoimmune disorders has begun a trans-
sively infused antibodies to deplete antigen-bearingformation from an armamentarium of nonspecific thera-
cells. This depletion is temporary and ceases throughpies that affect a wide range of cells and signaling path-
the continuous repopulation of the B lineage from pre-ways to targeted therapies that modulate specific
cursors residing within primary hematopoietic organs.cytokines (e.g., tumor necrosis factor and IL-1), cell
In contrast to the B cell malignancies, non-Hodgkin’stypes (e.g., CD3 T cells and CD20 B cells), or inhibit
lymphoma, and chronic lymphocytic leukemia, in whicha unique signaling pathway (Kamradt and Mitchison,
one or more proliferating B cell clones can be identified2001; Davidson and Diamond, 2001; Keystone, 2003;
at a cellular and molecular level, the identity and speci-Gottlieb, 2003; Shanahan et al., 2003). The advent of
ficity of the pathogenic B cell clones in autoimmunetargeted therapies in the treatment of human autoim-
diseases are rarely known. In a subset of lymphoma andmune diseases has not only significantly improved pa-
leukemia patients, the malignant B cell clones producetients’ lives and changed clinical therapeutic paradigms
low-affinity paraproteins (antibodies) that manifest auto-but has also led a renaissance in understanding patho-
immune paraneoplastic syndromes. These paraproteinsgenesis of human disorders (Anasetti et al., 1992; Wein-
bind a variety of self-antigens, including those expressedblatt et al., 1999; Lipsky et al., 2000; Pisetsky, 2000b;
on red blood cells (RBCs) that result in autoimmuneCohen et al., 2002; Kremer et al., 2003; Keystone et
hemolytic anemia (e.g., IgM cold agglutinin disease), oral., 2003; Edwards et al., 2004). Our insights into the
C1 esterase complement inhibitor that manifests clini-pathogenic roles of B cell dysfunction in human autoim-
cally with angioedema (Silberstein, 1994; Pascual et al.,mune diseases circa 2004 remain limited. While prophy-
1997; Ward, 2001). Treatment of the underlying lym-lactic or interventional preclinical studies in rodent mod-
phoma or leukemia and eradication of the malignant Bels of human diseases are enlightening, many of these
cell clone improves the associated clinical autoimmunegenetically homogeneous models do not translate well
manifestations. For most autoimmune diseases, how-into the heterogeneous nature of human biology and
ever, the mechanistic relationship between pathogenicdiseases. Hence, a challenge to drug discovery as well
B cells, their products (e.g., autoantibodies), and clinicalas human immunology is to understand how probing B
manifestations remains elusive. Nonetheless, the emerg-cell biology in human autoimmunity translates back to
ing findings suggest that B lineage depletion or modula-these preclinical models of human disease and then
tion might be beneficial and provides a basis to furtherapplying this new knowledge to advance patient care.
explore the role of B lineage function in human biology.In this discussion, we will review how therapies in human
autoimmune diseases have provided insights into our
expanding understanding of B cell functions in human Autoantibodies––Diagnosis and Pathogenesis
autoimmune disorders (Figure 1). Autoantibodies have served historically as the sine qua
The scientific routes of B cell modulation began with non to indicate a role for B cells in autoimmune diseases.
the elegant surgical approaches in birds and under- They provide diagnostic and prognostic criteria, play a
scored the importance of the Bursa of Fabricius in B requisite role in disease pathogenesis, and serve as
cell ontogeny (Cooper et al., 1965). This was followed surrogate markers for disease activity.
by pioneering work using anti-immunoglobulin (Ig) re- The first category, while not mutually exclusive with
the others, represents a large proportion of autoantibod-
ies and typically is not thought to play a role in disease*Correspondence: flavius@gene.com (F.M.); acc@gene.com (A.C.C.)
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Figure 1. Effector Mechanisms of Human and Mouse B Cell Autoimmunity
“Classic” antibody-dependent mechanisms are responsible either directly or through immune complexes for the pathogenesis of specific
autoimmune diseases. Several other mechanisms, including antigen presentation (APC), costimulatory functions (surface molecules and
secreted cytokines), and the ability to support de novo lymphoid tissue organization (neolymphogenesis) may explain other parts of B cell
involvement in complex autoimmune conditions.
AchR, acetylcholine receptor; GMB, glomerular basement membrane; FVIII, factor VIII; TSH, thyroid-stimulating hormone; RBC, red blood
cells; GPIIb-IIIa, glycoprotein IIb-IIIa; GPIb-IX, glycoprotein Ib-IX; Ag, antigen; B, B cell; T, T cell; FDC, follicular dendritic cell; DC, dendritic cell.
pathogenesis. However, the latter may merely reflect age in a variety of organs, including skin, lung, kidney,
blood vessels, and the nervous system (Pisetsky,our lack of understanding of antigen specificity and its
role in disease pathogenesis. Nonetheless, many anti- 2000a). However, this serologic marker is observed in
a variety of other autoimmune disorders, and the levelbodies provide highly sensitive and/or specific diagnos-
tic criteria for the presence of a specific clinical syn- of serum ANAs does not correlate with the severity of
clinical disease. Patients can have persistently high ANAdrome. For example, the presence of anti-nuclear
antibodies (ANA) serves as an extremely sensitive diag- titers despite the absence of clinical disease. Con-
versely, patients experience disease flares without anynostic test for systemic lupus erythematosus (SLE). This
autoimmune disorder is characterized by T, B, and my- alterations in ANA levels. Other types of autoantibodies
in SLE patients can also be used to aid diagnosis andeloid cell dysregulation that gives rise to immune com-
plex (IC)-mediated deposition and inflammatory dam- prognostication of patient subsets––the presence of
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anti-Sm antibodies is highly specific for SLE diagnosis, cryoglobulin production through the use of immunosup-
pressive therapies and, in severe cases, removal of theanti-RNP antibodies identify a subset of patients with
pathogenic complexes through plasma exchange.a different clinical course of mixed connective tissue
A role for ICs in autoimmune disorders is also sup-disease, anti-phospholipid antibodies are associated
ported by the genetic association of Fc receptor (FcR)with an increased risk of thrombotic events, anti-ribo-
polymorphisms and human disease. FcRs for IgG in-somal P antibodies identify patients with increased risk
clude the high-affinity FcRI (CD64) receptors and theof central nervous system disease, and anti-Ro (SSA)
low-affinity FcRII (CD32) and FcRIII (CD16) receptors.antibodies are causally linked with an increased risk for
Genetic polymorphisms for both low-affinity IgG recep-the development of complete heart block (CHB) in the
tors have been described (Ravetch and Bolland, 2001;newborns of SLE patients (Ruiz-Irastorza et al., 2002;
Binstadt et al., 2003). The major FcRIIA polymorphismReichlin, 2003; Buyon and Clancy, 2003). In the case of
resides at amino acid 131. FcRIIA(His131) confersanti-Ro antibodies, only 50% of women have symptom-
higher affinity for IC binding than FcRIIA(Arg131).atic SLE or Sjogren’s syndrome at the time their babies
His131/His131 phagocytes are more efficient in IC phag-are born with CHB. Yet, a large proportion of these
ocytosis and clearance than cells bearing the Arg131/asymptomatic women ultimately develop clinical SLE
Arg131 low-affinity receptor allelic genotype. The majorand Sjogren’s disease over the ensuing decade (Brucato
FcRIIIA polymorphism resides at amino acid 158.et al., 2002).
Val158 confers high-affinity binding while Phe158 con-Aside from rheumatologic disorders, examples of
fers low-affinity binding. Patients expressing two copiespathogenic autoantibodies include the anti-acetylcho-
of FcRIIA(Arg131/Arg131) or IIIA (Phe158/Phe158) re-line receptor (AChR) and anti-glomerular basement
ceptors have been reported in some studies but not inmembrane (GBM) antibodies in myasthenia gravis and
others to exhibit increased association with a numberGoodpasture’s syndrome, respectively. Anti-AChR anti-
of autoimmune diseases, including immune-mediatedbodies alter AChR organization on the postsynaptic neu-
thrombocytopenia (ITP), SLE, and multiple sclerosisronal plate and functionally block acetylcholine neuro-
(MS). These polymorphic differences may result not onlytransmission to induce muscle paralysis, in particular
in prolonged IC circulation, deposition, and tissue dam-impairment of diaphragmatic function, with progression
age but may enhance inflammatory and proliferative re-to respiratory failure and death (Vincent, 2002). The his-
sponses of FcR-bearing cells in disease.tological demonstration of these complement fixing an-
The ability of ICs to activate the complement cascadetibodies on myelinated fibers from affected patients and
and liberate proinflammatory complement degradationability of plasma exchange and intravenous immuno-
components that enhance IC clearance, augment phag-globulin (IVIG) to improve clinical course together sup-
ocyte activation, and modulate cellular and humoral im-port a pathogenic role for anti-AChR antibodies in MG
munity provide additional effector mechanisms by which(Richman and Agius, 2003). Binding of anti-GBM anti-
B cell products can contribute to disease (Holers, 2003;bodies to the 3 chain of type IV collagen in the lung
Walport, 2001a, 2001b). In preclinical models, inhibitionand kidneys results in pulmonary hemorrhage and glo-
of complement activation, using soluble forms of com-merulonephritis, respectively, the latter of which can
plement receptors or antibodies that bind complementprogress to renal failure. Suppression and removal of
degradation products, have demonstrated efficacy inthese pathogenic antibodies with immunosuppressive
preclinical models of ischemia-induced injury, lupus,agents and plasma exchange guide the therapeutic prin-
and collagen-induced arthritis (Weisman et al., 1990;ciples of anti-GBM disease (Hudson et al., 2003). Hence,
Couser et al., 1995; Wang et al., 1995, 1996). Translationboth of these pathogenic antibodies support a definitive
of some of these principles to the clinics are in progressrole for B lineage cells in human disease.
and will provide us with a greater understanding of these
effector pathways in autoimmune disease. A phase II
Immune Complexes, Complement, and Fc study of the anti-C5 inhibitor antibody eculizumab
Receptors in Disease Pathogenesis (5G1.1, Alexion Pharmaceuticals, Cheshire, CT) that pre-
The contributions of antibodies to disease are not solely vents the generation of the C5a anaphylatoxin has dem-
dependent upon their direct binding to end-organ tissue onstrated short-term safety and tolerability in patients
antigens but also through indirect mechanisms, includ- with rheumatoid arthritis (RA) and clinical benefit com-
ing IC formation, IC deposition, complement activation, pared to control patients (Tesser et al., 2001).
and FcR activation. These complement-activating ICs The therapeutic efficacy of IVIG in a limited subset
are found in many autoimmune disorders and deposit of autoimmune diseases, including ITP and MG, also
in a variety of tissues (e.g., kidney, lung, and blood ves- suggests roles for the contribution of antibodies, com-
sels) to cause end-organ damage (e.g., kidney failure, plement, and FcRs in B cell-mediated autoimmunity. ITP
pulmonary hemorrhage, and vasculitis, respectively). A is a clinical syndrome manifested by immune-mediated
classical example of an IC-mediated disease is the Hep- destruction of platelets (Beardsley, 2002). These pa-
atitis C-associated syndrome of mixed cryoglobulin- tients demonstrate high levels of autoantibodies di-
emia, in which complement activating IgG and IgM ICs rected against platelet surface glycoproteins that are
(containing Hepatitis C antigen) are deposited in the associated with accelerated platelet destruction (McMil-
skin, kidney, and peripheral nerves to induce cutaneous lan et al., 2001; McMillan, 2003). IVIG is manufactured
purpuric lesions, glomerulonephritis, and mononeuritis from pooled human plasma, and its therapeutic effects
multiplex, respectively (Trendelenburg and Schifferli, in ITP involve a multitude of mechanisms that include
2003). Treatment is dependent upon the extent of Fc blockade to decrease clearance of antibody-laden
platelets, inhibition of complement deposition, and moreinvolvement but traditionally geared toward decreasing
Immunity
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recently evidence for engagement of inhibitory FcRIIB genic pathways that are dependent or downstream of
B cell-initiated processes. To date, clinical results existreceptors. In a murine model of autoantibody-induced
to support the first two criteria while the third awaitsITP, the therapeutic effect of IVIG was dependent upon
more formal scientific validation.the induced expression of the inhibitory FcRIIB recep-
Clinical data for Rituxan in autoimmune diseases istor on splenic macrophages that, in turn, inhibits Fc-
emerging from a variety of double-blinded placebo-con-mediated opsonization of antibody-bound platelets
trolled trials though a large amount of data has already(Samuelsson et al., 2001). Similarly, the protective ef-
emerged from smaller Phase I/II studies and case seriesfects of IVIG in the K/BxN arthritis model are dependent
reports (Edwards et al., 2002; Silverman and Weisman,on the ability of CSF-1-dependent macrophages to
2003). The use of Rituxan in ITP led its entre´e into theupregulate FcRIIb expression on CSF-1-independent
realm of autoimmune diseases. In four case series re-“effector” macrophages (Bruhns et al., 2003). Hence,
ports, 33%–54% of ITP patients, who had failed stan-IVIG may function, in part, by inhibiting effector re-
dard of care corticosteroid and splenectomy therapies,sponses through this inhibitory receptor. Independent
experienced partial or complete responses to Rituxan,of mechanism, the limited therapeutic benefits of IVIG
in most cases in the absence of concomitant corticoste-in specific autoimmune disorders support a pathogenic
roids (Saleh et al., 2000; Stasi et al., 2001; Zaja et al.,role for antibodies and ICs in these diseases.
2003; Cooper et al., 2004). Interestingly, two patterns ofThe therapeutic application of plasma exchange has
clinical responses emerged. Early responders experi-provided additional support for the role of antibodies
enced immediate increases in platelet counts after theand ICs to implicate B lineage cells in disease (Saydain
first or second antibody infusion that were followed by aet al., 2002). Therapeutic apheresis is a technique by
continued rise until a peak count was achieved betweenwhich plasma and cellular components are separated
weeks 6 and 10. In contrast, late responders had minimaland autoantibodies, ICs, or toxins are removed from the
immediate effects. Rather, they had a delayed effect inplasma. This technique has been modified to include
which peak counts were achieved within the 6 to 8 weekprotein A immunoadsorption to specifically extract
period. These distinguishing patterns suggest that Ri-pathogenic autoantibodies and ICs. While plasma ex-
tuxan may operate through at least two distinct mecha-change has been used in a wide number of autoimmune
nisms in ITP. In the first, the effects of Rituxan arediseases, its therapeutic application is accepted as
too rapid to be accounted for by depletion of circulat-standard of care in only a handful of autoimmune dis-
ing antiplatelet antibodies but potentially could be ex-eases, including anti-GBM disease and MG, and ad-
panded through Fc receptor-mediated functions. In thejunctive therapy in cryoglobulinemia and ITP. Nonethe-
latter phase, the sustained effects may function throughless, modulation of circulating ICs and pathogenic
alterations in anti-platelet antibodies and/or interruptionantibodies by simple removal has proved effective in
of T-B cell cooperation or other B cell-dependent eventssome of these B lineage-mediated diseases.
in disease pathogenesis. To date, these small clinical
studies reveal no direct correlation of anti-platelet anti-B Cell Depletion
body levels with clinical responses and raise the like-
The development of therapeutics that specifically target
lihood of additional mechanisms by which B lineage cell
B cells during the past decade has provided an entre´e
depletion modulates ITP (see below).
to better translate preclinical observations into human
The use of Rituxan in autoimmune disorders is most
biology and disease. These therapeutics have been led advanced in the treatment of patients with rheumatoid
by the use of rituximab (Rituxan, Genentech, Inc., South arthritis (RA). This disease involves a multicellular inflam-
San Francisco, CA and Biogen-IDEC, Cambridge, MA; matory response involving infiltration of lymphocytes
Mabthera, F.Hoffman-LaRoche, Ltd., Basel, Switzer- and granulocytes, proliferation of synovial fibroblast and
land), a chimeric monoclonal antibody directed against macrophages, and neovascularization of the lining sur-
the CD20 molecule. CD20 is a transmembrane glycopro- rounding joints. This proliferative process not only in-
tein expressed exclusively on normal and malignant B duces swelling, erythema, and pain of multiple joints
cells. Its expression is regulated during B cell develop- but progress to destruction and loss of bone density
ment emerging in late pre-B cells and extinguished on and architecture. The diagnosis of RA is aided typically
plasma cells. Given the prominent historical role of auto- by the presence of low-affinity IgM rheumatoid factor
antibodies, the absence of CD20 on plasma cells that (RF) autoantibodies directed against the Fc portion of
presumably are responsible for producing autoantibod- IgG. In a multicenter randomized double blind controlled
ies raised fundamental skepticism in applying this ther- study of 161 patients, those treated with Rituxan and
apy to autoimmune diseases. Yet, the efficacious use a short course of corticosteroids in conjunction with
of Rituxan in a number of autoimmune disorders has methotrexate or cyclophosphamide achieved greater
brought into question some of the preconceptions of clinical responses than patients treated with corticoste-
the biology of B lineage cells in autoimmune disorders. roids and methotrexate alone (Shaw et al., 2003; Ed-
Ideally, one would design a B cell-depleting therapy for wards et al., 2004). Analysis of serologic changes in a
autoimmunity to meet several criteria: (1) deplete all smaller series of 22 RA patients demonstrated a 60%
or most pathogenic B lineage cells or their precursors decrease in IgM RF and 75% decrease in anti-cyclic
(assuming that pathogenic cells and their products citrullinated peptide (CCP) antibodies in Rituxan re-
have a reasonably short lifespan), (2) pathogenic B cell sponders (Cambridge et al., 2003). Despite the longer
repopulation should not occur or should be significantly half-life of IgG, when compared to IgM, IgG RF de-
delayed upon repletion from early bone marrow progeni- creased more rapidly and to a greater extent (80%) than
IgM RFs (60%) following Rituxan therapy. In contrast, notors, (3) interrupt or influence non-B cell effector patho-
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change in anti-pneumococcal capsular polysaccharide tors against Factor VIII, an important component of the
coagulation cascade, also demonstrate differences be-IgG antibodies and a 23% decrease in anti-tetanus tox-
oid IgG antibodies were detected 3 months following tween self and non-self antibodies. These patients have
circulating FVIII inhibitors (anti-FVIII autoantibodies), de-treatment. Similar serologic effects have been observed
in two additional studies with Rituxan treatment (De Vita spite immunosuppression with corticosteroids and che-
motherapeutic agents, which functionally compromiseet al., 2002; Tuscano, 2002). This preferential decrease
in autoantibodies suggests that autoreactive B cells and their coagulation cascade, that result in bleeding com-
plications requiring RBC transfusions. Treatment withtheir corresponding plasma cells may have a shorter
lifespan while non-self-reactive plasma cells are rela- Rituxan resulted in a rapid decrease in their acquired
FVIII inhibitor and return of their endogenous FVIII levelstively more resistant to Rituxan and have a longer lifespan.
Since RF is not thought to play a direct pathogenic (Wiestner et al., 2002). Interestingly, one of these four
patients had mild hemophilia A and received recombi-role in rheumatoid arthritis, as transfer of RF-positive
serum in the skg model of RA is not sufficient to confer nant human FVIII (rFVIII) perioperatively, which appears
to have triggered an increase in FVIII inhibitor activitydisease (Sakaguchi et al., 2003), the therapeutic efficacy
of Rituxan reported in these studies identifies B lineage and further compromised his already low FVIIIc level.
Administration of Rituxan in this patient resulted in rapidcells as playing a key, but undefined, pathogenic role
in RA. B cells exist as lymphoid aggregates within the resolution of the autoantibody (against endogenous
FVIII) whereas the alloantibody (anti-rFVIII) responsesynovium of RA patients and may function as APCs to
provide important costimulatory signals in promoting persisted for months. Hence, similar to the fate of serum
RF, the biologic effects of these autoreactive B cellseffector T cell expansion (Weyand and Goronzy, 2003).
Addition of antibodies that block T and B cell coopera- appear to be far shorter lived than non-self-reactive B
cells.tion results in loss of these T-B cell aggregates (Take-
mura et al., 2001). Hence, B cell depletion may remove In addition to ITP, RA, and FVIII deficiency, therapeutic
effects of Rituxan have been reported in small casea critical component of T-B cell cooperation required
for disease. While RF alone is not sufficient to induce series of patients with pemfigus vulgaris (anti-des-
moglein-3 antibodies) and pemfigus foliaceus (anti-des-disease, RF-containing ICs may promote synoviocytes
to induce local release of inflammatory factors and moglein-1 antibodies) (Salopek et al., 2002; Goebeler et
al., 2003; Dupuy et al., 2004). In addition to clinical bene-exacerbate the inflammatory cascade. Conversely, de-
creases in RF and other autoantibodies may attenuate fit, pathogenic antibody titers decrease, but do not dis-
appear, following Rituxan administration and return atthese local inflammatory ICs and result in clinical im-
provement. Additional clinical studies of synovial B cells relapse. In at least one patient, clinical relapse and auto-
antibody increase was documented in the complete ab-prior to and following Ritxuan therapy will be revealing
in dissecting the specific mechanistic roles of systemic sence of peripheral B cells, suggesting a complex rela-
tionship between B cells, autoantibodies, and clinicaland local (e.g., synovial) B cells in RA and the effects
of Rituxan on RA pathogenesis. effect. Patients with MG have similarly demonstrated
decreases in anti-AChR antibodies, which is accompa-Longer term follow-up analysis of a handful of Ri-
tuxan-treated RA patients have been reported and re- nied by a slow clinical improvement (Wylam et al., 2003).
Finally, patients with IgM-associated polyneuropathiesveal that most undergo clinical relapse. In the study
reported by Cambridge and colleagues, 13 of 15 re- with anti-MAG (myelin-associated glycoprotein) auto-
antibodies have also been reported to have decreasedsponders relapsed within 17 months following B cell
repletion. In all but one patient, return of autoantibodies anti-MAG titers and clinical improvement following Ri-
tuxan administration (Levine and Pestronk, 1999; Pes-preceded relapse. Return of autoreactive antibodies,
through their corresponding plasma cells and precur- tronk et al., 2003). In contrast, two patients with anti-
ganglioside IgG antibodies did not improve even up tosors, may occur through a stochastic recapitulation of
pathogenic events involving a new set of naive B cells 1 year following depletion (Rojas-Garcia et al., 2003).
This dichotomy of responsiveness does not simply re-freshly generated from the bone marrow. Supporting
this scenario are data on subset composition for repopu- flect differences between IgM and IgG autoantibodies
since other IgG autoantibodies are modulated by Ri-lating blood cells as well as their VH gene repertoire
assayed by single cell PCR (Rouziere et al., 2003). Pe- tuxan therapy.
The effects of Rituxan on autoreactive and non-self-ripheral B cells from patients with moderate to severe
RA have a large component of isotype-switched mem- reactive antibodies have only recently been studied in
SLE patients. Three open label studies have been re-ory cells with heavily somatically mutated VH genes.
During and immediately following B cell repletion, the ported (Leandro et al., 2002; Anolik et al., 2003;
Eisenberg, 2003). While the overall efficacy is unknownrepertoire is dominated by phenotypically naive cells
with germline VH regions. Preceding reemergence of at this time, the immunologic parameters in these
studies demonstrate a further disconnect betweenautoantibodies and clinical relapse, the peripheral B cell
repertoire begins reaccumulating mutations and slowly B cell depletion and reduction of anti-dsDNA antibodies.
Interestingly, these patients have a large percentageconverges to resemble the predepletion repertoire. To-
gether, these early studies suggest that pathogenic B of circulating plasmablasts (CD27CD20), memory
(CD27CD20), and/or germinal center (CD38CD20)cell clones and their progeny can be modulated by Ri-
tuxan therapy and that autoreactive and allogeneic re- B cells. Analysis of the effects of Rituxan on the survival
of these B cell subsets will likely provide greater insightssponses likely have distinct kinetics of longevity and
biology. into the half-life and survival factors that regulate these
germinal center (GC)-derived cells.Recent studies of four patients with circulatory inhibi-
Immunity
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B cell differentiation into Ig-secreting plasma cells has Plasma Cells
B cell pathogenesis in autoimmune diseases has beenbeen elegantly explored in humans through the investi-
gation of the CD40/CD40L axis (Arpin et al., 1995). GCs historically attributed to autoantibodies that, in either
soluble or IC forms, are thought to initiate local inflam-represents a major site to permit crosstalk of antigen-
activated T, B, and follicular dendritic cells to promote matory cascades. The plasma cell source of these auto-
antibodies is much less well characterized in humansT and B cell expansion and effector functions. In particu-
lar, the CD40/CD40L axis is critical within these GC with respect to exact phenotype, location, or longevity
(Arce et al., 2002; Hauser et al., 2003). Populations ofprocesses for appropriate generation of memory B cells
and long-lived CD38CD27 antibody-forming cells long-lived plasma cells have been well characterized in
response against foreign antigens (Manz et al., 1997;(plasmacytes). Blockade of the CD40/CD40L axis inhib-
its activation-induced cytidine deaminase-mediated so- Traggiai et al., 2003). These cells, in both mice and hu-
mans, are enriched in the bone marrow environment.matic hypermutation, Ig class switch, GC formation, and
maintenance and the generation of long-term B cell The existence of long-lived autoimmune plasma cells
has been demonstrated in murine models of SLE andmemory. Patients with inherited mutations of CD40L are
unable to undergo Ig class switch and develop elevated suggested in humans. Analysis of these cells in humans,
however, has proven difficult due to the extreme lowlevels of IgM but reduced levels of serum IgG and IgA.
Selective patients with active SLE have significantly frequency and poor understanding of their precursors
and intermediates. Although long- and short-lived termi-elevated numbers of circulating CD38IgD preswitch
GC cells, CD38IgDpostswitch GC cells, CD38CD27 nally differentiated plasma cells downregulate surface
expression of CD20, and hence would not be depletedmemory cells, and CD38 plasma cells. Some of these
cells have variable levels of inappropriate CD40L ex- by anti-CD20 therapies, very little is known about their
immediate precursors in autoimmune diseases. Thepression and in vitro can undergo spontaneous prolifer-
ation and Ig secretion that is blocked with an anti-CD40L minimal decreases observed in total serum Ig and more
drastic reductions in autoantibody levels following Ri-mAb (Grammer et al., 2003; Huang et al., 2002). Treat-
ment of SLE patients with an anti-CD40L antibody tuxan treatment suggest either different precursor sen-
sitivities to depletion or, alternatively, that autoantibody-(BG9588, 5c8, Biogen-IDEC, Inc.) resulted in substantial
decreases in anti-ds DNA antibody, proteinuria, and im- producing plasma cells are enriched in shorter-lived
subsets.proved clinical SLEDAI score (a conglomerate measure
of clinical and laboratory parameters relevant to the Regardless of whether autoantibodies originate from
long- or short-lived precursors, it is widely accepted thatseverity of SLE disease). Correspondingly, decreases
in CD38IgD preswitch GC cells and CD38 plas- most pathogenic autoantibodies increase their affinity
through somatic mutations. For normal immune re-macytes with less dramatic effects on CD38IgD
postswitch GC cells were observed in treated patients. sponses, this process occurs within the specialized GC
environment. Recent data from a murine model of RFHence, CD40/CD40L blockade may operate at multiple
levels, including inhibiting GC initiation, differentiation autoantibody generation, however, suggests that there
are situations in which high-rate somatic mutations canof GC cells to CD38 plasmacytes, and interfere with
GC maintenance in autoantibody generation. be generated outside of the GC (William et al., 2002).
Microdissection of dividing cell foci demonstrate thatTogether, the body of emerging clinical data involving
B cell depletion and modulation in a number of human mutations are readily detected at the T cell zone—red
pulp interface in immunoglobulin transgenic MLR/lprdiseases all indicate a clear pathogenic role for B lineage
cells, effector functions, and products in disease patho- mice, where the normal Fas/FasL mechanisms for main-
taining tolerance are compromised. Paralleling thesegenesis. Independent of the direct and indirect roles for
antibodies in disease, these data also demonstrate that observations, patients with Fas/FasL pathway defects
(human autoimmune lymphoproliferative syndrome),self-reactive B cells and their products likely exhibit
distinct properties as compared to non-self-reactive B with defects in B and T cell apoptosis, develop in both
cellular and humoral autoimmunity.cells. Additionally, studies of the CD40/CD40L axis fur-
ther indicate that targeting of specific subsets of down- The exact cellular source of autoantibodies in autoim-
mune diseases becomes important when one tries tostream B cell effector function is feasible and will be of
benefit in certain human autoimmune disorders. explain the large variability seen in autoantibody reduc-
tion in patients. Treatment of nonhuman primates with
clinically relevant doses of anti-CD20 antibodies demon-Mechanisms of B Cell Pathogenicity—Humans
strates significantly different rates for depletion of circu-and Mice
lating and lymphoid-laden B cells (Reff et al., 1994;In this final section, we will link observations on B cell
Schroder et al., 2003). Additionally, there appears to beeffector functions in human disease with those in murine
differential sensitivities to depletion of various B cellmodels of disease and discuss how these parallels
subsets (Vugmeyster et al., 2003). It is conceivable thatmight aid in understanding the mechanisms of action
the variable effects on autoantibodies may result fromfor B cell depleting therapies in human autoimmunity.
the differential depletion of these self- and non-self-We will begin by continuing the theme of potential differ-
reactive plasma cell precursors.ences in the precursors of self- and non-self-reactive
antibodies, then discuss non-antibody-dependent con-
tribution of B cells as antigen-presenting cells, and fi- Antibody-Independent Effector Functions
The antibody-independent contributions of B cells innally, review the role of B cells in lymphogenesis and
ectopic neolymphogenesis in disease pathogenesis. human autoimmunity have also been paralleled in mu-
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rine models of disease. The ability of B cells to alter Lymphogenesis and Neolymphogenesis
The newly recognized role of B cells in lymphogenesisT cell activation and expansion was suggested by the
generation of an IgH Tg NZB/W SLE-prone mouse strain and ectopic neolymphogenesis may also contribute to
autoimmunity and serve as a therapeutic mechanism byexpressing a germline immunoglobulin (Ig) transgene
(Wellmann et al., 2001). Despite a restricted B cell reper- which B cell depletion or modulation improves human
autoimmunity. Dissection of attraction, migration, andtoire, these Ig transgenic mice developed high titers
of anti-dsDNA autoantibodies but not IC deposits or retention signals have demonstrated that lymphoid or-
gans and structures are highly dependent on networksglomerulonephritis. They also had improved mortality,
when compared to their NZB/W littermates, and dis- of TNF family molecules, integrins, and chemokines (Fu
et al., 1997; Cyster, 1999; Ansel and Cyster, 2001). Inplayed reduced T cell activation. A similar finding of B
cell-mediated disease has also been demonstrated in generating appropriate lymphoid architecture, B cells
play an early requisite role through their interactionsthe New Zealand obese (NZO) diabetes-prone mouse
(Haskell et al., 2002). Hence, autoimmune B cells appear with organ stroma and provide a milieu permissive for
secondary seeding by T cells and dendritic cells. Thiscapable of driving T cells to mediate certain subsets of
autoimmune manifestations. These distinct contribu- sequence of events for neolymphogenesis was ele-
gantly demonstrated by the ectopic introduction of ations are consistent with the identification of genetic
elements in the NZM2140 SLE-prone mouse model in B cell chemoattractant in the pancreas that initiates a
cascade of cellular and developmental events leadingwhich clinical and serologic manifestations of disease
can be linked, in part, to T (the sle3 locus), B (sle2), and to the creation of a new lymphoid structure (Luther et
al., 2000). A similar dependence on B cells has alsoB-T components (sle1) (Nguyen et al., 2002).
The contributions of antibody-independent mecha- been demonstrated in splenic organogenesis as well as
normal M cell development in the gut (Ngo et al., 2001;nisms to B cell function is further illustrated in MLR/lpr
mice made deficient in their ability to secrete Ig but with Golovkina et al., 1999). The complementary scenario has
been attempted by pancreatic expression of a T cellintact membrane Ig B cells and B cell effector func-
tions—mIgM MRL/lpr (Chan et al., 1999). Despite the chemoattractant. However, in this parallel experimental
system, lymphoid organogenesis did not progress toabsence of secreted Ig and anti-ds DNA antibodies,
these mice still develop interstitial nephritis, vasculitis, the same stage as with B cells, demonstrating a cellular
hierarchy in lymphogenesis (Luther et al., 2002).and less, but still significant, glomerulonephritis and
mortality when compared with secretory sufficient MLR/ B cells appear not only important for the formation
but also maintenance of these structures. These obser-lpr. In contrast, JHD MLR/lpr mice rendered completely
B cell-deficient exhibit minimal disease and mortality vations on lymphogenesis formation and maintenance
may be important to the recent description of lymphoid-(Shlomchik et al., 1994). Hence, effector B cell functions,
independent of secreted antibody, are also of para- like follicles in joints and inflamed glands in patients
with RA and Sjogren’s syndrome, respectively (Weyandmount importance in disease development. A favored
hypothesis to explain these antibody-independent ef- and Goronzy, 2003; Groom et al., 2002). Hence, B cell
depletion or CD40/CD40L blockade could lead to disso-fects is the ability of B cells to present antigen to T cells
as part of the pathogenic process. Such a possibility lution of these organized pathogenic lymphoid infiltrates
and interfere with maintenance of long-lasting T helperclearly exists, though it should be pointed out that these
experimental systems utilize immunoglobulin heavy memory as well as dendritic cell localization and func-
tion (Moulin et al., 2000; Ngo et al., 2001). Looking atchain transgenes that can limit the autoreactive B cell
receptor repertoire. the B cell effector mechanisms in total, it is possible that
interrupting all or a combination of the above-describedDirect inhibition of B/T collaboration, through CD40/
CD40L blockade, has been demonstrated to be benefi- pathways is required for clinical efficacy. Further dissec-
tion of these mechanisms in ongoing clinical trials ascial in several mouse models of lupus. Anti-CD40L treat-
ment blocks both Ig class switching and somatic muta- well as complex models will be required to fully appreci-
ate the multiple B cell functions in immunity and disease.tion, reduces anti-dsDNA IgG antibodies, and induces a
variable period of general B and T cell unresponsiveness
(Kalled et al., 2001; Wang et al., 2003). In addition, CD40 Future of B Cell Therapies
is required for the development of CD8 memory T cell A final point of discussion for human clinical efficacy in
responses (Bourgeois et al., 2002). Together, these data autoimmune diseases is the potential lack of complete
demonstrate multiple mechanisms by which B/T interac- anti-CD20 B cell depletion in secondary lymphoid or-
tion, presumably through antigen presentation or vari- gans. Current protocols of Rituxan administration result
ous cosignals and cytokines, may promote T cell ef- in an excess of drug that should efficiently deplete all
fector functions in disease pathogenesis. Additionally, CD20 B cells. Explanations for the lack of complete
in MLR/lpr mice with B cells lacking 2-microglobulin, depletion, as has been observed in nonhuman primate
and hence MHC class I expression, the contribution of studies, could be diverse and span from intrinsic B cell
B cells to CD8 T cell activation can also occur indepen- resistance as well as factors derived from the local mi-
dent of antigen crosspresentation (self-antigen pre- croenvironment (Reff et al., 1994; Schroder et al., 2003).
sented on MHC class I to CD8 T cells) (Chan and Shlom- While intrinsic B cell resistance has been more difficult
chik, 2000). Together, these data open the possibility of to address and manipulate in humans, the local B cell
APC-dependent and APC-independent mechanisms for microenvironment with the multitude of cells and sur-
B cells in autoimmune mouse models of lupus and po- vival signals is of prime importance for additional clinical
intervention. It is conceivable that additional costimula-tentially in human disease.
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tory signals, such as CD40/CD40L, with effects on B ogy of self-reactive B lineage cells. The second half of
cell differentiation and survival could rescue them from this first decade promises to be even more exciting as
depletion. Such survival signals within these microenvi- the impact of these emerging B cell-directed therapies
ronments would not only protect B cells from death but in disease and their immunologic consequences will
could provide additional growth signals for the expan- likely not only improve patient survival and quality of life
sion of autoimmune B cells. In addition to CD40/CD40L, but will undoubtedly illuminate the multitude of B cell
blocking additional survival signals, such as BLys/BAFF functions in human immunity and autoimmunity.
and Toll-like receptors (TLR), would likely be beneficial
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